Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis

World Journal of Surgical Oncology

Zhenyu Zhang¹  Yachun Bie¹ 

[1] Department of Obstetrics and Gynecology, Beijng Chao-yang Hospital affiliated to Capital Medical University, 100020 Beijing, P. R. China

关键词: Meta-analysis;    Diagnoses;    HE4;    Serum;    Endometrial cancer (EC);   

Others  :  811159
DOI  :  10.1186/1477-7819-12-169

 received in 2014-02-26, accepted in 2014-05-09,  发布年份 2014

【 摘 要 】

Background

Endometrial cancer (EC) is a common female malignant cancer. The age of incidence has become younger than before. If the diagnosis is during stage I, then the survival rate is about 90%. To date, there are no specific tumor markers for endometrial cancer. We usually use serum CA125 to help in diagnosing it. However, a serum biomarker CA125 greater than 35 U/ml is not useful in diagnosing EC at an early stage. Now, human epididymis protein 4 (HE4) has been intensively studied, and has been described as a new marker for ovarian cancer. The goal of this study was to evaluate the clinical value of serum HE4 in the diagnosis of endometrial cancer by meta-analysis.

Methods

We used MEDLINE, EMBASE, Cochrane Library and CBM databases to search the literature. The meta-analysis was performed by using Meta-Disc 1.4 software.

Results

All data we obtained showed that the major advantage of HE4 lies in its specificity in endometrial cancer diagnosis. Its sensitivity in serum was not as high as expected. But this evidence is not enough.

Conclusions

Additional studies, particularly to evaluate HE4’s capability in identifying EC at an early stage, will be needed.

【 授权许可】

   
2014 Bie and Zhang; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983, 309:883-887.
• [2]Aggarwal P, Kehoe S: Serum tumour markers in gynaecological cancers. Maturitas 2010, 67:46-53.
• [3]Kirchhoff C: Molecular characterization of epididymal proteins. Rev Reprod 1998, 3:86-95.
• [4]Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN: HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 2010, 11:111-116.
• [5]Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008, 110:196-201.
• [6]Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, Tognon G, Ragnoli M, Romani C, Tassi RA, Caimi L, Odicino FE, Sartori E, Pecorelli S, Ravaggi A: Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med 2012, 50:2189-2198.
• [7]Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, Aloisi A, Luvero D, Cafa EV, Dugo N, Angelucci M, Benedetti-Panici P: The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol 2013, 34:571-576.
• [8]Omer B, Genc S, Takmaz O, Dirican A, Kusku-Kiraz Z, Berkman S, Gurdol F: The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumour Biol 2013, 34:2645-2650.
• [9]Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, Bergamelli S, Bandiera E, Tassi RA, Romani C, Todeschini P, Odicino FE, Facchetti F, Pecorelli S, Ravaggi A: Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer 2011, 104:1418-1425.
• [10]Zhang AM, Zhang P: [Clinical value of combined detection of serum human epididymal secretory protein E4 and CA(125) in the diagnosis of endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi 2012, 47:125-128.
• [11]Angioli R, Miranda A, Aloisi A, Montera R, Capriglione S, De CiccoNardone C, Terranova C, Plotti F: A critical review on HE4 performance in endometrial cancer: where are we now? Tumour Biol 2014, 35:881-887.
• [12]Plebani M, HE4 Study Group: HE4 in gynecological cancers: report of a European investigators and experts meeting. Clin Chem Lab Med 2012, 50:2127-2136.
• [13]Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, Widschwendter A: HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol 2012, 126:186-191.
• [14]Galgano MT, Hampton GM, Frierson HF Jr: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006, 19:847-853.
• [15]Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, Fink D, Heinzelmann-Schwarz V: No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011, 121:487-491.
• [16]Bolstad N, Oijordsbakken M, Nustad K, Bjerner J: Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol 2012, 33:141-148.